The Cooper Companies, Inc.

COO Healthcare Medical - Instruments & Supplies NASDAQ

Back to Search

$76.55

$-3.65 (-4.55%)

Open: $76.97 | High: $78.11 | Low: $75.00 | Prev Close: $80.20

Market Cap: $15.00B

Volume: 5.3M | Avg: 2.2M

Last updated: March 09, 2026 at 02:01 AM
Featured In

This stock appears in the following dashboards:

Price % Leaders
Ranked #21
Investment Rating
B

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 4/5
80%
Buy
ROE Score 3/5
60%
Neutral
ROA Score 4/5
80%
Buy
D/E Score 2/5
40%
Sell
P/E Score 1/5
20%
Strong Sell
P/B Score 3/5
60%
Neutral
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 552

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 25
Financial Health 85
Growth 60
Market Sentiment 10
Risk 50
Lower is better
Valuation 22
Momentum 0
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 40.94
P/B Ratio 1.80
P/S Ratio 3.61
EPS $1.87
Beta 1.03
Shares Outstanding 195.98M
Price Range & Moving Averages
52-Week High $89.83
52-Week Low $61.78
SMA 50 $82.13
SMA 200 $74.82
Earnings
Next Earnings May 28, 2026 12:00 PM ET
Financial Ratios
Margins
Gross Margin 64.2%
Operating Margin 17.2%
Net Margin 9.7%
Returns
ROE 4.8%
ROA 3.2%
Liquidity & Leverage
Debt/Equity 0.30
Current Ratio 1.34
Quick Ratio 0.79
Balance Sheet
Total Assets $12.39B
Total Liabilities $4.16B
Total Equity $8.24B
Cash $110.60M
Total Debt $2.78B
Net Debt $2.67B
Income Statement
Revenue $4.09B
Gross Profit $2.48B
Operating Income $682.90M
Net Income $374.90M
EBITDA $1.05B
Revenue/Share $21.11
Cash Flow
Operating CF $796.10M
CapEx $362.40M
Free Cash Flow $433.70M
Book Value/Share $42.52
Tangible Book/Share $14.83
Equity/Share $42.52
Technical Indicators
RSI (14) 26.18 Oversold
MACD
-0.28 Signal: 0.22
Volatility 20.61%
Trading Signal Oversold
Performance & Returns
Total Returns
1 Year -6.54%
Risk-Adjusted Returns
Sharpe Ratio -0.15 Poor
Volatility (Ann.) 34.54% Moderate
vs S&P 500 (SPY)
COO (1Y) -6.54%
S&P 500 (1Y) +13.03%
Alpha (Excess Return) -19.58%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 52 peers in Healthcare
Metric COO Sector Avg Percentile
P/E Ratio 40.94 27.4 79%
P/B Ratio 1.8 -19.56 30%
ROE (%) 4.83% -9.38% 23%
Net Margin (%) 9.67% 9.31% 45%
Stock Score 552 543.0 53%
1Y Return (%) -6.54 % +8.43 % 33%
Percentile: 0% = worst in sector, 100% = best in sector
📊 Historical Price Analysis (Last 200 Days)

Loading chart...

Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
COO $76.55 $80.88 $81.79 $82.26 $82.02 $74.80 26.18 -0.28 20.61% 1686936 Strong Short Bearish Stack
Candlestick Patterns

There wasn't any recognizable pattern for the COO stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
COO The Cooper Companies (COO) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Neutral zacks.com Read More
COO Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term Neutral zacks.com Read More
COO Investing in The Cooper Companies (COO)? Don't Miss Assessing Its International Revenue Trends Neutral zacks.com Read More
COO Is The Cooper Companies (COO) a Solid Growth Stock? 3 Reasons to Think "Yes" Positive zacks.com Read More
COO Here's Why The Cooper Companies (COO) is a Strong Growth Stock Positive zacks.com Read More
Recent Insider Trading

No recent insider trading data available for COO

Company Information

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

CEO Albert G. White
Employees 16000
Country US
IPO Date 1983-01-21
Exchange NASDAQ
Website https://www.coopercos.com
Sector Healthcare
Industry Medical - Instruments & Supplies
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
ISRG

Intuitive Surgical, Inc.

Price: $486.29
Change: -2.10%
Market Cap: $1726B
P/E: 61.87
Score: C (626)
View Details
BDX

Becton, Dickinson and Company

Price: $168.65
Change: -0.76%
Market Cap: $6110B
P/E: 27.60
Score: E (502)
View Details
RMD

ResMed Inc.

Price: $252.87
Change: -0.96%
Market Cap: $3691B
P/E: 25.26
Score: C (647)
View Details
WST

West Pharmaceutical Services, Inc.

Price: $245.86
Change: +0.62%
Market Cap: $1770B
P/E: 36.21
Score: D (542)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.